JP2002167331A - Digestion and absorption accelator - Google Patents
Digestion and absorption accelatorInfo
- Publication number
- JP2002167331A JP2002167331A JP2000366055A JP2000366055A JP2002167331A JP 2002167331 A JP2002167331 A JP 2002167331A JP 2000366055 A JP2000366055 A JP 2000366055A JP 2000366055 A JP2000366055 A JP 2000366055A JP 2002167331 A JP2002167331 A JP 2002167331A
- Authority
- JP
- Japan
- Prior art keywords
- absorption
- digestion
- weight
- feed
- phosphatidylcholine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000010521 absorption reaction Methods 0.000 title claims description 28
- 230000029087 digestion Effects 0.000 title claims description 28
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims abstract description 26
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 230000000694 effects Effects 0.000 claims description 19
- 230000001737 promoting effect Effects 0.000 claims description 19
- 244000144972 livestock Species 0.000 claims description 12
- 229940124532 absorption promoter Drugs 0.000 claims description 10
- 230000001079 digestive effect Effects 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 150000003904 phospholipids Chemical class 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 235000008935 nutritious Nutrition 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 150000002327 glycerophospholipids Chemical class 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 235000015816 nutrient absorption Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- BWSIKGOGLDNQBZ-LURJTMIESA-N (2s)-2-(methoxymethyl)pyrrolidin-1-amine Chemical compound COC[C@@H]1CCCN1N BWSIKGOGLDNQBZ-LURJTMIESA-N 0.000 description 1
- 206010016251 Fat tissue increased Diseases 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 101000607626 Homo sapiens Ubiquilin-1 Proteins 0.000 description 1
- 102220547770 Inducible T-cell costimulator_A23L_mutation Human genes 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 208000036364 Normal newborn Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- 102100039934 Ubiquilin-1 Human genes 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- -1 amyl alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000008103 phosphatidic acids Chemical class 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- AWUCVROLDVIAJX-VKHMYHEASA-N sn-glycerol 1-phosphate Chemical compound OC[C@H](O)COP(O)(O)=O AWUCVROLDVIAJX-VKHMYHEASA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
Landscapes
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Jellies, Jams, And Syrups (AREA)
- Non-Alcoholic Beverages (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、ホスファチジルコ
リンを有効成分とする消化吸収促進剤に関する。本発明
の消化吸収促進剤は、消化吸収促進効果により、乳幼児
の発育を促進することができ、また、体重が減少した高
齢者や術後の患者をはじめとする傷病者の体重増加を促
進することができるので、直接経口投与する栄養補助剤
や、飲食品に添加する添加剤として利用することができ
る。また、本発明の消化吸収促進剤は、消化吸収促進効
果により、動物の発育を促進することができるので、直
接経口投与する栄養補助剤や、飼料に添加する添加剤と
して利用することができる。また、本発明は、ホスファ
チジルコリンを配合して消化吸収促進効果を賦与した飲
食品に関する。さらにまた、本発明は、ホスファチジル
コリンを配合して消化吸収促進効果を賦与した家畜用飼
料に関する。TECHNICAL FIELD The present invention relates to a digestion / absorption promoter containing phosphatidylcholine as an active ingredient. The digestion-absorption promoter of the present invention can promote the growth of infants and children by the effect of promoting digestion and absorption, and also promote weight gain of injured persons, including elderly persons who have lost weight and post-operative patients. Therefore, it can be used as a nutritional supplement directly administered orally or as an additive to be added to foods and drinks. In addition, the digestion and absorption promoter of the present invention can promote the growth of animals by the effect of promoting digestion and absorption, and thus can be used as a nutritional supplement directly administered orally or an additive to be added to feed. In addition, the present invention relates to a food or drink which has a phosphatidylcholine and imparts an effect of promoting digestion and absorption. Furthermore, the present invention relates to a feed for livestock which has a phosphatidylcholine blending effect and has an effect of promoting digestion and absorption.
【0002】[0002]
【従来の技術】近年の高齢化社会においては、加齢に伴
う生理的な運動機能低下、脂質代謝系の機能低下、免疫
機能の低下、消化吸収能の低下や老年病の増加が問題と
なっている。これらが原因となって高齢者の体重が減少
し、基礎体力が低下することが、さらなる症状の悪化を
もたらしているというのが現状である。そこで、高齢者
の体重減少による基礎体力の低下をいかに抑えるかが重
要な課題となっている。また、体重の減少による基礎体
力の低下という観点では、傷病者についても同様であ
る。現在、高齢者や傷病者における体重減少及び体重回
復の遅延への対応は、対症療法的な栄養補助食品の投与
によって行われているが、量を摂取することが困難であ
るため、少ない食事でも効率よく消化吸収され、体重が
増加するような食品が求められていた。また、栄養吸収
能力の未熟な幼児期においては、栄養吸収率の良い素材
の供与は、成長を助けるという意義があり重要である。2. Description of the Related Art In an aging society in recent years, physiological problems such as aging, a decrease in the function of lipid metabolism, a decrease in immune function, a decrease in digestion and absorptive capacity, and an increase in geriatric diseases have become problems. ing. Under these circumstances, the weight loss of the elderly and the decrease in basic physical strength due to these causes the further worsening of symptoms. Therefore, it is an important issue how to suppress a decrease in basic physical strength due to weight loss of the elderly. In addition, from the viewpoint of a decrease in basic physical strength due to a decrease in weight, the same applies to a victim. Currently, the elderly and the disabled respond to weight loss and delayed body weight recovery through the use of symptomatic dietary supplements. There has been a demand for foods that can be efficiently digested and absorbed and increase body weight. In addition, in infants with a poor nutrient absorption ability, the provision of a material having a high nutrient absorption rate is significant and important in supporting growth.
【0003】さらに、近年、畜産物生産の効率化が求め
られ、家畜の繁殖や育種における損失を如何に防止する
かが重要な課題となっている。一般的に、生まれてきた
新生仔の体重が普通の新生仔の平均体重よりも軽かった
場合、その後の食環境が同じであれば、その体重差が解
消されることはないといわれている。一般には、出産仔
数が多ければ多い程、体重の少ない仔が生まれる可能性
が高まる。そして、体重の少ない仔が生まれた場合、そ
の仔は家畜としての経済価値を著しく損なうこともあ
る。そこで、このような新生仔の体重を、平均的な体重
まで回復させようとすると、より多量に栄養価の高い飼
料を与える必要がある。しかし、栄養価の高い飼料を多
量に与えることは、生産効率低下の一因となってしまう
ので、このような新生仔に与える、安価でかつ栄養価の
高い飼料が求められていた。また、安価でかつ栄養価の
高い飼料の利用は、家畜の成長を早めることで生産効率
が向上する効果をもたらすという意義があり重要であ
る。Further, in recent years, there has been a demand for more efficient production of livestock products, and it has become an important issue how to prevent losses in livestock breeding and breeding. In general, it is said that if the weight of a born newborn is lighter than the average weight of a normal newborn, the difference in weight will not be eliminated if the subsequent eating environment is the same. In general, the greater the number of offspring, the greater the likelihood of having lower weight offspring. And, when a baby with a low weight is born, the baby can significantly impair the economic value of livestock. Therefore, in order to restore the weight of such a newborn baby to an average weight, it is necessary to feed a larger amount of a nutritious feed. However, feeding a large amount of a nutritious feed causes a decrease in production efficiency. Therefore, an inexpensive and nutritious feed to be given to such newborn babies has been demanded. In addition, the use of inexpensive and highly nutritious feed is significant and important because it has the effect of accelerating the growth of livestock and improving production efficiency.
【0004】一方、ホスファチジルコリンは、リン脂質
の一種であり、卵黄、大豆、乳等に存在しており、生体
内では、細胞膜や血清リポタンパク質の構成成分として
分布している。リン脂質は、グリセロ・リン脂質とスフ
ィンゴ・リン脂質の2群に大別される。グリセロ・リン
脂質はL-α-グリセロリン酸(sn-glycerol-3-phosphat
e)の誘導体である。グリセロリン酸の1位と2位に脂
肪酸がエステル結合したものがホスファチジン酸(phos
phatidic acid)である。さらに、リン酸部分に種々の
アミルアルコールやポリオールなどがエステル結合し、
ホスファチジルコリンやホスファチジルエタノールアミ
ンといった種々のグリセロ・リン脂質を形成する。牛乳
及び大豆由来のリン脂質の構成成分を表1に示した(菰
田衛著、レシチン−その基礎と応用、幸書房発行、199
1)。[0004] On the other hand, phosphatidylcholine is a kind of phospholipid and is present in egg yolk, soybean, milk and the like, and is distributed in vivo as a constituent of cell membranes and serum lipoproteins. Phospholipids are broadly divided into two groups, glycerophospholipids and sphingophospholipids. Glycerophospholipids are L-α-glycerophosphate (sn-glycerol-3-phosphat)
e) is a derivative of Phosphatidic acid (Phosphatic acid (phos)
phatidic acid). Furthermore, various amyl alcohols and polyols are ester-bonded to the phosphoric acid moiety,
It forms various glycerophospholipids such as phosphatidylcholine and phosphatidylethanolamine. Constituent components of phospholipids derived from milk and soybeans are shown in Table 1 (Ed. Komoda, Lecithin-Basics and Applications, published by Koshobo, 199).
1).
【0005】[0005]
【表1】 [Table 1]
【0006】このリン脂質は、細胞や血球などの生体
膜の維持物質として作用する、膜流動性を高め、膜結
合性タンパク質や受容器の作用を高める、生体膜の作
用の一つである、濃度勾配に逆行した物質の選択的透過
性があるが、これらの機能に関わる、細胞レベルで、
免疫反応にも影響を及ぼす、といった様々な作用を有す
ることが知られている。しかし、リン脂質に消化吸収促
進効果があるということは、今まで報告されていなかっ
た。[0006] The phospholipid acts as a maintenance substance for biological membranes such as cells and blood cells, enhances membrane fluidity, and enhances the action of membrane-bound proteins and receptors. At the cellular level, there is a selective permeability of substances that go against the concentration gradient, but these functions are involved.
It is known to have various effects such as affecting the immune response. However, it has not been reported that phospholipids have a digestive absorption promoting effect.
【0007】[0007]
【発明が解決しようとする課題】本発明は、上述したよ
うな乳幼児の栄養吸収能力が低いという問題、高齢者や
傷病者の体重減少による基礎体力低下の問題や、家畜の
新生仔の体重差による生産効率低下の問題に着目し、乳
幼児、高齢者、傷病者及び家畜を対象とした経口摂取可
能な消化吸収促進剤を提供することを課題とする。DISCLOSURE OF THE INVENTION The present invention relates to problems such as the above-mentioned problems of poor absorption of nutrients of infants and infants, a problem of a decrease in basal physical strength due to weight loss of the elderly and the sick, and a difference in weight of newborn domestic animals. It is an object of the present invention to provide an orally ingestible digestion and absorption promoter for infants, the elderly, the sick and the livestock, focusing on the problem of reduced production efficiency.
【0008】[0008]
【課題を解決するための手段】本発明者らは、上記課題
を解決するために鋭意研究を進めていたところ、リン脂
質の一種であるホスファチジルコリンに消化吸収促進作
用があることを見出し、本発明を完成するに至った。Means for Solving the Problems The present inventors have made intensive studies to solve the above problems, and found that phosphatidylcholine, a kind of phospholipid, has a digestive absorption promoting effect. Was completed.
【0009】[0009]
【発明の実施の形態】本発明では、消化吸収促進剤の有
効成分としてホスファチジルコリンを使用する。ホスフ
ァチジルコリンとしては、卵黄、大豆及び乳由来のもの
等を使用することができる。消化吸収促進剤の有効成分
として、これらの素材の濃縮物、あるいはこれらの素材
よりホスファチジルコリンを精製して純度を高めたもの
等を使用すればよい。例えば、乳やホエータンパク質濃
縮物(WPC)等の乳製品をエーテルやアセトンで抽出して
得られる画分、バターを加温融解することにより得られ
るバターカードやバターセラムを含む水性画分、これら
を透析、硫安分画、ゲル濾過、等電点沈殿、イオン交換
クロマトグラフィーで精製する方法や、溶媒分画により
精製する方法(特開平3−47192号公報、M.Faure,Bull.
Soc.Biol.,32,503(1950))等により得られる純度を高め
たホスファチジルコリン等を挙げることができる。DESCRIPTION OF THE PREFERRED EMBODIMENTS In the present invention, phosphatidylcholine is used as an active ingredient of a digestion and absorption promoter. As phosphatidylcholine, those derived from egg yolk, soybean and milk can be used. As an active ingredient of the digestion and absorption enhancer, a concentrate of these materials or a product obtained by purifying phosphatidylcholine from these materials to increase the purity may be used. For example, dairy products such as milk and whey protein concentrate (WPC) fractions obtained by extraction with ether or acetone, aqueous fractions containing butter curd or butter serum obtained by heating and melting butter, these Is purified by dialysis, ammonium sulfate fractionation, gel filtration, isoelectric point precipitation, ion exchange chromatography, or by solvent fractionation (JP-A-3-47192, M. Faure, Bull.
Soc. Biol., 32, 503 (1950)).
【0010】本発明のホスファチジルコリンを有効成分
とする消化吸収促進剤は、ホスファチジルコリン単独で
もよいし、糖、タンパク質、脂質等を構成成分として含
んでいてもよい。また、液体、粉末や錠剤等の形態を適
宜とることができ、栄養補助剤として直接、経口投与す
ることができる。なお、消化吸収促進効果を発揮するた
めには、投与する全飲食品に対するホスファチジルコリ
ンの割合が0.1重量%以上となるように本発明の消化吸
収促進剤を投与することが好ましい。また、本発明の消
化吸収促進剤を飲食品や家畜飼料に添加し、消化吸収促
進効果を賦与した飲食品や家畜飼料として使用すること
ができる。なお、飲食品や家畜飼料に消化吸収促進効果
を賦与するためには、ホスファチジルコリンが最終製品
中で0.1重量%以上となるように添加することが好まし
い。また、高純度のホスファチジルコリンを用いなくて
も、有効量のホスファチジルコリンを強化できるリン脂
質組成物を使用してもよい。次に、実施例及び試験例を
示し、本発明をさらに詳しく説明する。The digestion and absorption enhancer containing phosphatidylcholine of the present invention as an active ingredient may be phosphatidylcholine alone or may contain sugar, protein, lipid and the like as constituents. In addition, it can be in the form of a liquid, powder, tablet or the like as appropriate, and can be directly orally administered as a nutritional supplement. In order to exhibit the digestion and absorption promoting effect, it is preferable to administer the digestion and absorption enhancer of the present invention so that the ratio of phosphatidylcholine to all administered foods and drinks is 0.1% by weight or more. Further, the digestion-absorption promoter of the present invention can be added to foods and drinks and livestock feeds, and can be used as foods and drinks and livestock feeds having a digestive absorption promotion effect. In order to impart a digestive absorption-promoting effect to food and drink or livestock feed, it is preferable to add phosphatidylcholine in an amount of 0.1% by weight or more in the final product. Also, a phospholipid composition capable of fortifying an effective amount of phosphatidylcholine without using high-purity phosphatidylcholine may be used. Next, the present invention will be described in more detail with reference to Examples and Test Examples.
【0011】[0011]
【実施例1】(ホスファチジルコリンの調製)ホエータ
ンパク質濃縮物(WPC)の10重量%水溶液にプロテアー
ゼを作用させて得られた反応液をクロロホルム−メタノ
ール(2:1)溶液で抽出した後、濃縮し、さらにアセト
ン抽出して複合脂質画分を得た。次に、この複合脂質画
分をフロロシリルカラムクロマトグラフィー処理し、ク
ロロホルム−メタノール溶液で段階抽出してホスファチ
ジルコリンを得た。このホスファチジルコリンを薄層ク
ロマトグラフィ−処理した後、ディットマー試薬で発色
し、デンシトメトリー法で測定したところ、ホスファチ
ジルコリンの含有率は96.3%であった。このようにして
得られたホスファチジルコリンは、消化吸収促進剤とし
てそのまま利用可能である。Example 1 (Preparation of phosphatidylcholine) A reaction solution obtained by allowing a protease to act on a 10% by weight aqueous solution of whey protein concentrate (WPC) was extracted with a chloroform-methanol (2: 1) solution, and then concentrated. The mixture was further extracted with acetone to obtain a complex lipid fraction. Next, the complex lipid fraction was subjected to fluorosilyl column chromatography and stepwise extracted with a chloroform-methanol solution to obtain phosphatidylcholine. After the phosphatidylcholine was subjected to thin-layer chromatography, the color was developed with a Dittmer reagent, and the content of the phosphatidylcholine was 96.3% as measured by densitometry. The phosphatidylcholine thus obtained can be used as it is as a digestion and absorption promoter.
【0012】[0012]
【試験例1】(新生仔ラットに対する発育促進効果)表
2に示した配合に従って、試験飼料及び対照飼料を調製
し、生後1週齢のSD系ラット7匹を1群として、試験飼
料群には試験飼料、対照飼料群には対照飼料を、2週齢
になるまでの1週間、胃にカテーテルを装着し、それぞ
れ一定量投与した。[Test Example 1] (Growth-promoting effect on neonatal rats) Test feeds and control feeds were prepared according to the formulation shown in Table 2, and seven 1-week-old SD rats were grouped into a test feed group. , A control feed was administered to the test stomach, and a control feed was administered to the stomach for one week until reaching 2 weeks of age, and a certain amount of each was administered to the control feed group.
【0013】[0013]
【表2】 [Table 2]
【0014】なお、これらの飼料については、エネルギ
ーはともに151.8kcal/100mlであり、ホスファチジルコ
リンの含有量は試験飼料が0.545g/100ml、対照飼料は0.
045g/100mlであった。そして、投与期間中の体重変化、
摂取飼料量および飼料効率、投与終了後の体長、小腸重
量及び小腸筋肉層厚を測定した。その結果を表3に示
す。The energy of these feeds was 151.8 kcal / 100 ml, the content of phosphatidylcholine was 0.545 g / 100 ml in the test feed, and 0.1% in the control feed.
It was 045 g / 100 ml. And weight changes during the administration period,
The feed intake and feed efficiency, body length, small intestinal weight and small intestinal muscle layer thickness after administration were measured. Table 3 shows the results.
【0015】[0015]
【表3】 [Table 3]
【0016】この結果について、マン・ホイットニー検
定により解析を行ったところ、試験飼料群の体重は、対
照飼料群の体重より有意に上昇しており、また飼料効率
も有意に上昇していた。また、試験飼料群の体長、小腸
重量及び小腸筋肉層厚は、対照飼料群のそれらより有意
に大きくなっていることから、この体重増加は、体長が
伸びたこと及び小腸等の支持組織が成長したためであ
り、脂肪組織が増えたいわゆる肥満ではないことがわか
る。Analysis of the results by the Mann-Whitney test revealed that the weight of the test feed group was significantly higher than that of the control feed group, and that the feed efficiency was also significantly increased. In addition, since the body length, small intestine weight and small intestinal muscle layer thickness of the test feed group were significantly larger than those of the control feed group, this weight increase was due to the increase in body length and the growth of supporting tissues such as the small intestine. It can be seen that this is not so-called obesity in which adipose tissue has increased.
【0017】これにより、ホスファチジルコリンを摂取
することにより飼料効率が高まり、その結果ラットの発
育が促進されたことが明らかとなった。なお、試験期間
中においては、ラットに何ら病態的な変化は認められな
かった。Thus, it has been clarified that ingestion of phosphatidylcholine increased feed efficiency, and as a result, the growth of rats was promoted. During the test period, no pathological changes were observed in the rats.
【0018】[0018]
【試験例2】(老化促進マウスに対する消化吸収促進効
果)表4に示した配合に従って、試験飼料及び対照飼料
を調製し、老化モデルである11週齢のSAMP/8系マウス
(老化促進マウス)7匹を1群として、試験飼料群には
試験飼料、対照飼料群には対照飼料を、28日間、それ
ぞれ一定量投与した。また、通常モデルである11週齢の
SAMR/1系マウス(通常マウス)についても、老化促進マ
ウスと同様の試験を行った。[Test Example 2] (Effect of promoting digestion and absorption on aging-promoting mouse) According to the composition shown in Table 4, a test feed and a control feed were prepared, and an 11-week-old SAMP / 8 mouse (aging-promoting mouse) was used as an aging model. The test feed group and the control feed group were each administered a fixed amount of the test feed group and the control feed group for 28 days. In addition, the normal model of 11 weeks old
SAMR / 1 mice (normal mice) were also tested in the same manner as the aging-promoting mice.
【0019】[0019]
【表4】 [Table 4]
【0020】そして、投与期間中の体重変化、摂取飼料
量および飼料効率、投与終了後の小腸重量及び小腸筋肉
層厚を測定した。その結果を表5に示す。Then, changes in body weight, feed intake and feed efficiency during the administration period, small intestinal weight and small intestinal muscle layer thickness after the administration were measured. Table 5 shows the results.
【0021】[0021]
【表5】 [Table 5]
【0022】この結果について、クラスカル・ワーリス
検定により解析を行ったところ、老化促進マウス、通常
マウスともに試験飼料群の体重は、対照飼料群の体重よ
り有意に上昇しており、また飼料効率も有意に上昇して
いた。また、試験飼料群の小腸筋肉層厚は、対照飼料群
のそれらより有意に大きくなっていることから、この体
重増加は、小腸内の支持組織が成長したためであり、脂
肪組織が増えたいわゆる肥満ではないことがわかる。The results were analyzed by the Kruskal-Wallis test. The body weight of the test feed group was significantly higher than that of the control feed group, and the feed efficiency was significantly higher in both the senescence-accelerated mouse and the normal mouse. Was rising. Also, since the small intestinal muscle layer thickness of the test feed group was significantly larger than that of the control feed group, this weight increase was due to the growth of the supporting tissue in the small intestine, and the so-called obesity in which the fat tissue increased. It turns out that it is not.
【0023】この体重の増加は、通常マウスと比較して
老化促進マウスにおいて顕著に認められた。このこと
は、本発明により、加齢による体重減少を回復させるこ
とができることを示している。なお、試験期間中におい
ては、マウスに何ら病態的な変化は認められなかった。This increase in body weight was remarkably observed in senescence-accelerated mice as compared with normal mice. This indicates that the present invention can restore weight loss due to aging. Note that no pathological changes were observed in the mice during the test period.
【0024】[0024]
【実施例2】(消化吸収促進剤の製造)表6に示した配
合に従って成分を混合し、加圧成型して、消化吸収促進
剤を製造した。Example 2 (Production of digestion and absorption promoter) The components were mixed in accordance with the formulation shown in Table 6 and molded under pressure to produce a digestion and absorption promoter.
【0025】[0025]
【表6】 [Table 6]
【0026】[0026]
【実施例3】(消化吸収促進効果を賦与した飲料の製
造)表7に示した配合に従って成分を混合し、容器に充
填した後、加熱滅菌して、消化吸収促進効果を賦与した
飲料を製造した。Example 3 (Production of a Beverage Having an Effect of Promoting Digestion and Absorption) The components were mixed according to the composition shown in Table 7, filled in a container, and then sterilized by heating to produce a beverage having an effect of enhancing digestion and absorption. did.
【0027】[0027]
【表7】 [Table 7]
【0028】[0028]
【実施例4】(消化吸収促進効果を賦与したゼリーの製
造)表8に示した配合に従って成分を混合し、容器に充
填した後、加熱滅菌し、冷却して、消化吸収促進効果を
賦与したゼリーを製造した。Example 4 (Manufacture of jelly imparting digestive absorption promoting effect) Ingredients were mixed according to the composition shown in Table 8, filled in a container, heat sterilized, and cooled to impart digestive absorption promoting effect. Jelly was manufactured.
【0029】[0029]
【表8】 [Table 8]
【0030】[0030]
【実施例5】(消化吸収促進効果を賦与したブタ用飼料
の製造)表9に示した配合に従って成分を混合し、消化
吸収促進効果を賦与したブタ(多胎動物)用飼料を製造
した。Example 5 (Manufacture of pig feed having an effect of promoting digestion and absorption) Ingredients were mixed in accordance with the composition shown in Table 9 to produce a feed of pig (multiple fetus) having an effect of promoting digestion and absorption.
【0031】[0031]
【表9】 [Table 9]
【0032】この飼料を生後2ヶ月のブタに1ヶ月間投
与したところ、その体重は同日齢の平均的なブタの体重
よりも上昇していた。なお、このブタには何ら病態的な
変化は認められなかった。When this feed was administered to a two-month-old pig for one month, the weight was higher than that of an average pig of the same age. No pathological changes were observed in this pig.
【0033】[0033]
【実施例6】(消化吸収促進効果を賦与したウシ用飼料
の製造)表10に示した配合に従って成分を混合し、消
化吸収促進効果を賦与したウシ(単胎動物)用飼料を製
造した。Example 6 (Production of cattle feed provided with digestive absorption promoting effect) Ingredients were mixed according to the composition shown in Table 10 to produce cattle (single animal) feed provided with digestive absorption promoting effect.
【0034】[0034]
【表10】 [Table 10]
【0035】この飼料を生後3ヶ月のウシに1ヶ月間投
与したところ、その体重は同日齢の平均的なウシの体重
よりも上昇していた。なお、このウシには何ら病態的な
変化は認められなかった。When the feed was administered to a three-month old cow for one month, the weight was higher than that of an average cow of the same age. No pathological changes were observed in this cow.
【0036】[0036]
【発明の効果】本発明の消化吸収促進剤は、日常的な経
口投与により、極めて安全に消化吸収促進効果を発揮す
る。その消化吸収促進効果により、乳幼児の発育を促進
することができ、また、体重が減少した高齢者や傷病者
の体重増加を促進することができるので、乳幼児、高齢
者及び傷病者に対する栄養補給に極めて有用である。ま
た、その消化吸収促進効果により、家畜の体重増加を促
進することができるので、家畜の生産効率向上に極めて
有用である。The digestion and absorption enhancer of the present invention exerts the digestion and absorption promotion effect extremely safely by daily oral administration. The effect of promoting digestion and absorption can promote the growth of infants and infants, and also can promote the weight gain of elderly and sick persons who have lost weight. Extremely useful. In addition, the effect of promoting digestion and absorption can promote weight gain of livestock, which is extremely useful for improving the production efficiency of livestock.
フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) // A23K 1/16 303 A23L 2/00 F 2/26 Fターム(参考) 2B150 AB01 BC01 DA20 DC08 DD57 4B017 LC03 LG04 LK06 LL09 4B018 LB01 LB08 LE01 MD45 ME14 MF08 4B041 LC10 LD02 LK05 4C086 AA01 AA02 DA41 MA01 MA04 MA52 NA14 ZA69 Continued on the front page (51) Int.Cl. 7 Identification symbol FI theme coat II (reference) // A23K 1/16 303 A23L 2/00 F 2/26 F term (reference) 2B150 AB01 BC01 DA20 DC08 DD57 4B017 LC03 LG04 LK06 LL09 4B018 LB01 LB08 LE01 MD45 ME14 MF08 4B041 LC10 LD02 LK05 4C086 AA01 AA02 DA41 MA01 MA04 MA52 NA14 ZA69
Claims (3)
消化吸収促進剤。1. A digestion / absorption promoter comprising phosphatidylcholine as an active ingredient.
収促進効果を賦与した飲食品。2. A food or drink which has a phosphatidylcholine and a digestive absorption promoting effect.
収促進効果を賦与した家畜用飼料。3. Livestock feed containing phosphatidylcholine and having an effect of promoting digestion and absorption.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000366055A JP2002167331A (en) | 2000-11-30 | 2000-11-30 | Digestion and absorption accelator |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000366055A JP2002167331A (en) | 2000-11-30 | 2000-11-30 | Digestion and absorption accelator |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2002167331A true JP2002167331A (en) | 2002-06-11 |
Family
ID=18836732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000366055A Pending JP2002167331A (en) | 2000-11-30 | 2000-11-30 | Digestion and absorption accelator |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2002167331A (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6167461A (en) * | 1984-09-06 | 1986-04-07 | Mori Sangyo Kk | Production of healthy food |
JPH02142448A (en) * | 1988-11-25 | 1990-05-31 | Snow Brand Milk Prod Co Ltd | Sterilized liquid nutritive agent |
JPH0998726A (en) * | 1995-05-15 | 1997-04-15 | Gist Brocades Nv | Animal feed composition |
JPH09121781A (en) * | 1995-11-08 | 1997-05-13 | Miyoshi Oil & Fat Co Ltd | Lecithin-containing powder |
JPH09131163A (en) * | 1995-11-09 | 1997-05-20 | Miyoshi Oil & Fat Co Ltd | Lecithin-containing powder |
JPH11269074A (en) * | 1998-03-18 | 1999-10-05 | Snow Brand Milk Prod Co Ltd | Digestant for lipid |
-
2000
- 2000-11-30 JP JP2000366055A patent/JP2002167331A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6167461A (en) * | 1984-09-06 | 1986-04-07 | Mori Sangyo Kk | Production of healthy food |
JPH02142448A (en) * | 1988-11-25 | 1990-05-31 | Snow Brand Milk Prod Co Ltd | Sterilized liquid nutritive agent |
JPH0998726A (en) * | 1995-05-15 | 1997-04-15 | Gist Brocades Nv | Animal feed composition |
JPH09121781A (en) * | 1995-11-08 | 1997-05-13 | Miyoshi Oil & Fat Co Ltd | Lecithin-containing powder |
JPH09131163A (en) * | 1995-11-09 | 1997-05-20 | Miyoshi Oil & Fat Co Ltd | Lecithin-containing powder |
JPH11269074A (en) * | 1998-03-18 | 1999-10-05 | Snow Brand Milk Prod Co Ltd | Digestant for lipid |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3856214T2 (en) | Diet compositions and methods of using bile acid activated lipase | |
JP3195594B2 (en) | A food composition containing a milk-derived phospholipid. | |
KR20070054739A (en) | Total enteral nutritious composition | |
JP2007246404A (en) | Learning ability-improving agent | |
TW201306752A (en) | Methods for improving tolerance, digestion, and lipid soluble nutrient absorption in an infant, toddler, or child | |
KR101094693B1 (en) | Skin conditioning agent | |
AU2005332128B2 (en) | Food composition for stimulating growth comprising fraction isolated from mammalian colostrum or milk whey | |
NZ573375A (en) | Visceral fat accumulation inhibitor, and agent for promoting the increase in and/or inhibiting the decrease in blood adiponectin level | |
AU2009205116B2 (en) | Liver function-protecting agent | |
KR20080108523A (en) | Fat accumulation inhibitor | |
JP3581010B2 (en) | Lipid digestion and absorption function improver | |
EP2221057A1 (en) | Sense-improving agent | |
JP3544493B2 (en) | Nutrition composition for infants | |
Polskin et al. | Secretion of vitamin D in milks of women fed fish liver oil | |
EA011075B1 (en) | Dry powdered milk formula | |
CN117481199A (en) | Premature/low birth weight infant food for promoting growth and development, and preparation method and application thereof | |
CN107529805A (en) | Composition comprising choline and its derivative, preparation method and use | |
JP2016535734A (en) | Composition comprising choline and derivatives thereof, use and preparation method thereof | |
CN103431411A (en) | Milk calcium orally fast dissolving tablet convenient to be taken by infants and production method thereof | |
JP3690820B2 (en) | Nutritional composition for infants | |
BR112021002467A2 (en) | compositions and methods for treating mastitis | |
JP7025112B2 (en) | BDNF production promoter | |
JP2002167331A (en) | Digestion and absorption accelator | |
JPH10262607A (en) | Nutrient composition for infant | |
CN113545399A (en) | Dairy product and method for producing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071029 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110316 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110823 |